Stoke Therapeutics (NASDAQ:STOK) Insider Sells 1,051 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 1,051 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $26.16, for a total transaction of $27,494.16. Following the completion of the sale, the insider directly owned 19,059 shares in the company, valued at approximately $498,583.44. This represents a 5.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

• On Tuesday, September 1st, Barry Ticho sold 5,545 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.67, for a total transaction of $170,065.15.
• On Tuesday, August 18th, Barry Ticho sold 4,767 shares of Stoke Therapeutics stock. The shares were sold at an average price of $32.03, for a total transaction of $152,687.01.
• On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.04, for a total transaction of $208,391.04.

Stoke Therapeutics Price Performance

STOK stock traded down $0.39 during midday trading on Friday, hitting $25.62. The company’s stock had a trading volume of 581,420 shares, compared to its average volume of 783,759. Stoke Therapeutics, Inc. has a twelve month low of $20.32 and a twelve month high of $40.22. The company’s fifty day moving average price is $29.99 and its 200 day moving average price is $31.21. The stock has a market capitalization of $1.65 billion, a P/E ratio of -7.67 and a beta of 1.26.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The business had revenue of $9.32 million for the quarter, compared to analyst estimates of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. Equities analysts expect that Stoke Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Stoke Therapeutics in the 2nd quarter valued at $192,307,000. Jupiter Topco LLC acquired a new stake in Stoke Therapeutics during the 2nd quarter valued at $59,358,000. Troluce Capital Advisors LLC bought a new position in Stoke Therapeutics during the first quarter worth $21,255,000. BVF Inc. IL boosted its position in Stoke Therapeutics by 36.7% during the fourth quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock worth $71,912,000 after purchasing an additional 608,578 shares during the period. Finally, Wellington Management Group LLP increased its holdings in shares of Stoke Therapeutics by 13.7% in the second quarter. Wellington Management Group LLP now owns 3,519,301 shares of the company’s stock valued at $115,152,000 after purchasing an additional 423,601 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently commented on STOK shares. The Goldman Sachs Group reissued a “buy” rating on shares of Stoke Therapeutics in a research report on Thursday, September 10th. Wedbush boosted their price target on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Guggenheim reiterated a “buy” rating and set a $60.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Stoke Therapeutics in a report on Friday, August 7th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Stoke Therapeutics in a research note on Friday, August 21st. They issued an “overweight” rating and a $40.00 target price for the company. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $44.25.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc is a biotechnology company developing genetic medicines for severe diseases caused by inadequate protein expression. The company’s approach, known as TANGO (Targeted Augmentation of Nuclear Gene Output), uses antisense oligonucleotides to selectively modulate pre-messenger RNA splicing and increase production of functional proteins from disease-associated genes.

Stoke’s lead program is zorevunersen (STK-001), an investigational antisense oligonucleotide designed to increase functional NaV1.1 protein expression in people with Dravet syndrome, a severe genetic epilepsy caused primarily by mutations in the SCN1A gene.